Greg Yap

Greg Yap is a Partner at Menlo Ventures and a Health Innovators Fellow at The Aspen Institute. Greg serves as a Board Member and Investor in multiple healthcare and life science companies including Ophelia, Scribe Therapeutics, Genesis Therapeutics, H1, Particle Health, Delfi Diagnostics, Riva Health, and Vital Labs, Inc. Greg holds an MBA from Stanford University and an AB in Molecular Biology from Princeton University.